Guided Therapeutics (GTHP) Equity Average (2016 - 2025)
Historic Equity Average for Guided Therapeutics (GTHP) over the last 14 years, with Q3 2025 value amounting to -$5.6 million.
- Guided Therapeutics' Equity Average fell 1684.92% to -$5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year decrease of 1684.92%. This contributed to the annual value of -$4.3 million for FY2024, which is 2998.95% down from last year.
- Per Guided Therapeutics' latest filing, its Equity Average stood at -$5.6 million for Q3 2025, which was down 1684.92% from -$2.8 million recorded in Q2 2025.
- In the past 5 years, Guided Therapeutics' Equity Average registered a high of -$1.9 million during Q1 2024, and its lowest value of -$9.4 million during Q1 2021.
- Moreover, its 5-year median value for Equity Average was -$4.2 million (2022), whereas its average is -$4.3 million.
- Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 6560.53% in 2021, then crashed by 3761.67% in 2024.
- Guided Therapeutics' Equity Average (Quarter) stood at -$5.3 million in 2021, then skyrocketed by 47.41% to -$2.8 million in 2022, then plummeted by 34.73% to -$3.7 million in 2023, then crashed by 31.53% to -$4.9 million in 2024, then decreased by 14.2% to -$5.6 million in 2025.
- Its Equity Average was -$5.6 million in Q3 2025, compared to -$2.8 million in Q2 2025 and -$2.4 million in Q1 2025.